Background Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy is the mostfrequently employed strategy for patients with highgrade osteosarcoma. However, the contribution of neoadjuvant chemotherapy compared with postoperative adjuvant chemotherapy has not been tested rigorously in patients with nonmetastatic high-grade pelvic osteosarcoma. Questions/purposes (1) Does neoadjuvant chemotherapy followed by delayed surgery offer a survival benefit to patients with nonmetastatic high-grade pelvic osteosarcoma compared with immediate surgery and adjuvant chemotherapy? (2) Is the timing of chemotherapy and surgery associated with a difference in the survivorship free from local recurrence and the risk of complications? (3) Is the threshold of 90% necrosis after neoadjuvant chemotherapy appropriate to distinguish responders from nonresponders in patients with pelvic osteosarcoma? Methods Between 2000 and 2015, our center treated 112 patients with nonmetastatic high-grade primary pelvic osteosarcoma, of whom 93 underwent tumor resection with chemotherapy. Four patients (4%) were lost to followup before 24 months but were not known to have died; the remaining 89 patients were included in this retrospective study. Based on the timing of surgery and chemotherapy, patients were analyzed in two groups: (1) neoadjuvant chemotherapy followed by delayed surgery and adjuvant chemotherapy (n = 56; mean followup of 61 months, range 27-137 months), and (2) immediate surgery followed by adjuvant chemotherapy (n = 33; mean followup of 77 months, range 25-193 months). The total duration and intensity of chemotherapy was similar in both groups. During the period in question, we generally used neoadjuvant therapy followed by delayed surgery and adjuvant chemotherapy when patients received their biopsies in our center. We typically used immediate surgery with adjuvant chemotherapy when patients initially refused chemotherapy or when they had severe pain or poor walking function. Patients in the neoadjuvant chemotherapy group had a higher proportion of sacral infiltration; other factors such as sex, age and tumor size were well balanced between groups. We compared overall survival and local recurrence-free survival rates between the two groups. We completed univariate log-rank tests and multivariate Cox analyses in all patients to identify factors associated with survival and local recurrence using the Kaplan-Meier method.
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Introduction
In the past 30 years, great progress has been achieved in treating patients with nonmetastatic osteosarcoma with adjuvant chemotherapy with doxorubicin, cisplatin, highdose methotrexate and ifosfamide. Five-year survival rates have increased 60% to 70% [2, 10, 25] . Neoadjuvant chemotherapy, generally delivered about 8 to 10 weeks before surgery, offers several advantages. It treats micrometastatic disease early, reducing the risk of distant metastasis. The primary tumor response may improve the ability to achieve negative margins in limb-resection procedures. It also allows time to plan limb-salvage and reconstructive procedures. After tumor removal, assessing the necrosis on the primary tumor predicts outcome; better histologic necrosis is associated with better survival [21, 29] . However, not all osteosarcoma patients respond well to chemotherapy. Delayed surgery means the patient is exposed to a large tumor burden for a prolonged time while he or she undergoes potentially marginally effective chemotherapy, which could increase the chance of distant metastasis. The only prospective trial investigating the benefit of neoadjuvant chemotherapy, POG8651, reported that there was no survival advantage for patients with extremity lesions who underwent presurgical chemotherapy [14] .
Patients with pelvic osteosarcoma have poorer 5-year survival rates, ranging from 4% to 32% compared with 70% to 75% 5-year survival rates of patients with osteosarcoma of the extremities [8, 11, 12, 15, 17, 19, 25, 26, 28] . Larger tumor size at diagnosis, poor response to chemotherapy and difficulties in obtaining negative margins during resection are blamed in the poor prognosis of pelvic osteosarcomas. Currently, most patients with pelvic osteosarcomas are treated with the same strategy as extremity lesions, namely neoadjuvant chemotherapy followed by delayed surgery and adjuvant chemotherapy. However, we questioned the survival benefit of neoadjuvant chemotherapy in this specific group of patients who have a larger tumor burden and a potentially poorer response to chemotherapy. There were two major concerns about choosing immediate surgery in pelvic sarcoma: (1) A previous study in our center showed that we had more wound problems in the pelvic region after neoadjuvant chemotherapy [18] , which would postpone the resumption of chemotherapy after surgery and result in more drug-resistant clones and a poor prognosis [16] . (2) Few patients had a necrosis rate of more than 90%, and no obvious decrease in tumor size was observed in most of our previous patients, which indicated a potentially poorer response to chemotherapy; this might make surgeons feel more comfortable about removing the tumor first. Furthermore, studies in which a chemotherapy change was attempted in patients who had a poor response to chemotherapy have not demonstrated improved survival in nonresponders [6, 13, 24, 30] . The evidence is not clear that neoadjuvant chemotherapy is necessary for nonmetastatic pelvic osteosarcoma patients [11, 14, 26, 28] .
We therefore sought to compare patients with nonmetastatic high-grade primary pelvic osteosarcoma treated in one institute with conventional chemotherapy and surgery who were retrospectively divided into two groups according to the timing of surgery. Specifically, we asked (1) Does neoadjuvant chemotherapy followed by delayed surgery offer a survival benefit for patients with nonmetastatic high-grade pelvic osteosarcoma compared with immediate surgery and adjuvant chemotherapy? (2) Is the timing of chemotherapy and surgery associated with a difference in the survivorship free from local recurrence and the risk of complications? (3) Is the threshold of 90% necrosis after neoadjuvant chemotherapy appropriate to distinguish responders from nonresponders in patients with pelvic osteosarcoma?
Patients and Methods
Between July 2000 and June 2015, our center surgically treated 146 patients with high-grade pelvic osteosarcomas, 112 of whom had no evidence of metastasis at diagnosis. Of those, 93 patients underwent tumor resection with chemotherapy. Nineteen patients were treated with other methods, including four patients older than 60 years who refused chemotherapy. Another 15 patients returned to their local hospitals for postoperative chemotherapy. In addition, 21 patients were treated with chemotherapy or radiation therapy without surgery during the same period because they were deemed inoperable by the surgeons or they refused surgery. Based on the timing of surgery, 93 patients were retrospectively divided into two groups: (1) neoadjuvant chemotherapy followed by delayed surgery and adjuvant chemotherapy, and (2) immediate surgery followed by adjuvant chemotherapy. Four patients (4%), two in each group, were lost to followup before 24 months but were not known to have died; they were excluded from this study. The remaining 89 patients were included in this retrospective study. We had 56 patients in the neoadjuvant chemotherapy group and 33 patients in immediate surgery group. Twenty patients in the neoadjuvant group and 14 in the surgery group remain disease-free. The median followup time for patients treated with neoadjuvant chemotherapy was 61 months (range, 27-137 months) and for those treated with immediate surgery followed by adjuvant chemotherapy it was 77 months (range, 25-193 months) .
During the period in question, we generally used neoadjuvant therapy followed by delayed surgery and adjuvant chemotherapy when patients received their biopsy in our center, had full adherence to treatment, or when sacral nerve involvement was found at diagnosis. We typically used immediate surgery with adjuvant chemotherapy when patients initially refused chemotherapy, or when they had severe pain or poor walking function.
The diagnosis of high-grade osteosarcoma, necrosis analysis and margin analysis were done by pathologists (KS and DS) in Peking University People's Hospital. We retrospectively evaluated the efficacy of neoadjuvant chemotherapy using RECIST1.1 [9] .
Baseline chest CT, radionuclide bone scans or positron emission tomography (PET)/CT was used to assess metastatic disease. Patient followup included a chest CT, pelvic radiographs, and CT scans every 3 months, as well as radionuclide bone scans every 6 months for 2 years after diagnosis. During the third year after diagnosis, chest and pelvic CTs were taken every 6 months and yearly thereafter.
For patients in the neoadjuvant chemotherapy group, therapy was delivered according to the Peking University People's Hospital-Osteosarcoma (PKUPH-OS) regimen, which began in 2008 ( Fig. 1) . Patients who had immediate surgery underwent a similar regimen 2 weeks postoperatively. Before 2008, there was no specific regimen, but patients underwent at least three cycles of doxorubicin combined with cisplatin, high-dose methotrexate and ifosfamide as neoadjuvant chemotherapy, and they underwent another several cycles of these four drugs after surgery to equal 1 year of total therapy time. Lesion locations were recorded according to the Enneking and Dunham pelvic classification system [10] . A type IV lesion involved part of the sacrum. Tumor resection with wide margins was attempted in every procedure. The reconstruction methods were individualized for each patient We collected patients' demographic characteristics and disease-specific variables from the database, including sex, age (< 20 years, 20-40 years or > 40 years), maximum tumor size at diagnosis (< 10 cm or $ 10 cm), sacral infiltration (with or without, according to imaging at diagnosis), time of diagnosis (before or after 2008), surgery type (limb-salvage or amputation), margin (wide or marginal resection was recorded as an adequate margin whereas intralesional resection was recorded as an inadequate margin) and wound problems (dehiscence and deep infection). Necrosis analysis was available in 51 of 56 patients who received neoadjuvant chemotherapy. Devitalized bone replantation was used in three patients, so necrosis analysis was not feasible. The other two patients were treated more than 10 years ago. Only four patients had a necrosis rate of more than 90%. Twenty-three patients had a necrosis rate of more than 60%. Margins were available in 74 patients (83%; Table 1 ). Patients in the neoadjuvant chemotherapy group had a higher proportion of sacral infiltration (52% versus 24%; p = 0.009). There were no differences in other characteristics between the two groups. Univariate analysis showed that sex was not associated with survival (p = 0.961). Older age (hazard ratio [HR], 0.426; 95% confidence interval [CI], 0.202-0.898; p = 0.025) and sacral infiltration (HR, 2.014; 95% CI, 1.141-3.555; p = 0.016) were associated with poor prognosis. In the 74 patients where margins were available, an adequate margin was associated with good prognosis (HR, 0.197; 95% CI, 0.104-0.373; p < 0.001). Six of 56 patients (11%) in the neoadjuvant group and three of 33 patients (9%) in the immediate surgery group received amputation as the initial surgical treatment. At diagnosis, they all had large tumors with important vessels or nerves involved. These nine patients with amputation had a poor prognosis; however, we believe it was determined by the tumor size and biology not by the performance of an amputation. Evaluation of neoadjuvant chemotherapy was done according to RECIST1.1 [9] (Table 2) . Five patients had a partial response, and six patients showed progressive disease. Most patients had stable disease after chemotherapy.
We used the Fisher's exact test to investigate the prevalence of different variables in the two groups. Descriptive statistics were used to display demographic data. KaplanMeier analysis was used to determine overall survival (OS), event-free survival (EFS), and recurrence-free survival. We calculated EFS with time zero defined as the date of diagnosis and censored at the date of last followup, local recurrence, distant metastasis, or death. We defined recurrence-free survival from the time of surgery to the date of local recurrence. In the univariate analysis, we compared groups with a log-rank test, and we performed subsequent Cox proportional hazard analysis on variables to identify factors associated with survival and local recurrence. A p value < 0.05 considered significant. Analysis was performed in SPSS software package (SPSS Inc, Chicago, IL, USA).
Ethical approval for the study was provided by the ethics committee of Peking University People's Hospital in Beijing, China. All data used in the study was obtained from existing medical records in our hospital and written informed consent was not required.
Results
Is There a Survival Benefit to Neoadjuvant Chemotherapy?
With the numbers available, no survival benefit was found in the patients treated with neoadjuvant chemotherapy followed by delayed surgery compared with the group treated with immediate surgery and adjuvant chemotherapy (Fig. 2) . At 5 years, the overall survival (OS) was 42% (95% CI, 33-52) for all patients in this study, it was 43% (95% CI, 30-56) for the neoadjuvant chemotherapy group, and 40% (95% CI, 25-55) for the immediate surgery group; p = 0.709. The overall event-free survival (free from local recurrence and distant metastasis) was 37% (95% CI, 28-46); for the neoadjuvant chemotherapy group it was 36% (95% CI, 24-47) versus 39% (24-53) for the immediate surgery group; p = 0.636. One patient in the immediate surgery group developed a solitary lung metastasis 26 months after diagnosis and underwent immediate surgical resection. The patient had no evidence of disease at 52 months followup. In the neoadjuvant group, one patient had a local recurrence at 11 months and another patient had nodules in a single lung lobe at 15 months; both underwent a second resection of the relapsed lesions and were disease-free at 25 months and 28 months, respectively. All three patients received chemotherapy after their second resection with four to six cycles of ifosfamide combined with etoposide.
After controlling for confounders such as sex, tumor size, surgery type and time of diagnosis, only age < 40 (HR, 0.499; 95% CI, 0.254-0.978; p = 0.043) and adequate margin (HR, 0.206; 95% CI, 0.108-0.392; p < 0.001) remained independent factors associated with overall survival.
Neoadjuvant Chemotherapy, Risk of Local Recurrence and Complications
We found no difference in the 5-year local recurrencefree survival rate in each group: 68% (95% CI, 57-78) underwent a secondary operation, including 12 amputations. Prognosis for patients with local recurrence was extremely poor with a median survival of 8 months (range, 2-27 months) after recurrence. Only three patients who had a local recurrence were alive at last followup. Wound dehiscence and deep infection were the most common complications (Table 1) . With the numbers available, we could not detect a difference in the proportion of wound dehiscence or infection between the neoadjuvant and postoperative chemotherapy groups. In the neoadjuvant group, 17 of 56 patients (30%) developed wound dehiscence versus six of 33 patients (18%) in the postoperative chemotherapy group (p = 0.156). Four of 56 patients (7%) in the neoadjuvant group developed an infection compared with three of 33 patients (9%; p = 0.242) treated with postoperative chemotherapy. We did not analyze implant-related complications, such as loosening or prosthesis breakage, because we believed they had no association with the timing of surgery.
Is 90% Necrosis Following Neoadjuvant Chemotherapy a Good Threshold?
With the numbers available, there was no difference in survival between patients whose tumors demonstrated more than 90% necrosis and those who did not (75%; 95% CI, 38-100 versus 41%; 95% CI, 28-55; p = 0.015); however, only four of 51 patients in the delayed surgery group demonstrated 90% necrosis. We were missing necrosis data for five patients; three because they had devitalized bone replantation and two because they were treated more than 10 years ago. When analyzing tumor necrosis as a continuous variable, we found that patients with more tumor necrosis after treatment had greater overall survivorship (p = 0.016). Although a few patients had more than 90% necrosis, a better overall survival was observed in the group with more than 60% necrosis. Five-year OS was 60% (95% CI, 41-79) in patients with a necrosis rate greater than or equal to 60% and 33% (95% CI, 18-48) in patients with a necrosis rate less than 60% (p = 0.022; Fig.  3 ). Among 23 patients who had 60% or more necrosis that Fig. 3 Results of our survival analysis based on the proportion of tumor necrosis showed that overall survival for patients with a more than 60% necrosis compared with less than 60%. Necrosis of more than 60% showed better prognosis (p = 0.022).
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were defined as fair responders, three had local recurrence, four developed a distant metastasis and three experienced both. The 5-year EFS for these patients was 56% (95% CI, 38-74). Among 24 patients who had a necrosis rate of less than 60%, four developed a local recurrence, nine had distant metastasis and seven experienced both, with a 5-year EFS 27% (95% CI, 13-41; p = 0.012).
Discussion
In recent decades, neoadjuvant chemotherapy followed by delayed surgery and adjuvant chemotherapy has become the accepted strategy for high-grade osteosarcoma; however, its value with respect to survival compared with adjuvant chemotherapy has not been shown. In our study, we could not demonstrate an advantage in either survival or local control for patients with pelvic osteosarcoma and who were treated with neoadjuvant chemotherapy.
Limitations
This study had several limitations. Selection bias is the most important limitation. During the period in question, we had some general indications for the choice of surgery time as mentioned above. However, as a retrospective study, we are not certain that these indications were rigorously adhered to. The choice of immediate surgery was deeply impacted by the patients' desires. These patients usually had more pain (or were less tolerant of pain) and were more determined to have the tumor removed immediately. Other limitations should be considered in our study. The choice of whether to give neoadjuvant chemotherapy was not standardized by protocol or specific criteria; rather individual surgeons made the choice on a patient-to-patient basis. Fortunately, it turned out that there was no obvious difference in sex, age, time of treatment (before or after 2008), or maximum tumor size between the two groups. Patients in the neoadjuvant chemotherapy group had a higher proportion of tumors that infiltrated the sacrum. Usually, we tried to preserve the sacral nerves. We used neoadjuvant chemotherapy before resections that involved the sacrum, believing that it might be possible to preserve sacral nerve roots and improve function despite a close margin. There was no standard chemotherapy protocol, and the sequence and combination of four agents used before 2008 was different from what was used later in the study. We did not consider this a disqualifying weakness because there was no observed difference in survival when various protocols based on the same four agents were delivered according to previous reports [6, 20, 21, 30] . Different surgeons operated during the 15-year period. The differences among the surgeons should be considered as confounders when interpreting the result. However, both groups faced the same problem. At 51 patients, our population was not large enough to draw a robust conclusion in the Cox proportional hazard analysis in patients with various amounts of tumor necrosis after neoadjuvant chemotherapy, but we did observe a survival benefit in those who had greater than 60% necrosis. Besides, time to diagnosis, tolerance to chemotherapy and time to resumption of chemotherapy after definitive surgery were also confounding and should be further analyzed. A prospective trial is needed to confirm our observations.
In this study, we found no survival benefit in the neoadjuvant chemotherapy group for pelvic osteosarcoma. Preoperative neoadjuvant chemotherapy was first adopted in 1970s [1, 7] to allow time for planning limb-salvage and reconstructive procedures. However, with advances in surgical skills and reconstruction materials, patients do not need to wait for surgery any more. One randomized trial compared immediate and delayed definitive surgery in patients with extremity lesions and detected no survival differences [14] . A retrospective study from the Memorial Sloan-Kettering Cancer Center that evaluated 279 patients, 24 of whom had primary axial lesions [23] , also found no differences. Another large retrospective study on secondary osteosarcoma that compared 157 patients with primary surgery and 1451 patients with preoperative chemotherapy detected no survival differences [3] . However, these studies mainly focused on extremity lesions. We were unable to find research studying pelvic osteosarcoma with respect to the timing of chemotherapy in relation to surgery. Patients with pelvic lesions have 5-year survivorship of only 4% to 32%, which is lower than the 70% to 75% in patients with extremity lesions [8, 11, 12, 15, 17, 19, 25, 26, 28] . On one hand, immediate resection of the primary tumor may delay chemotherapy initiation to allow wound healing and result in possible distant metastasis. In our study, we planned to deliver chemotherapy 2 or 3 weeks after surgery, but in three of 33 patients (9%) with immediate surgery, chemotherapy was postponed to more than 4 weeks because of wound problems. On the other hand, a previous study in our center showed that we had more wound problems after neoadjuvant chemotherapy in the pelvic region [18] , which would postpone the resumption of chemotherapy postoperatively, result in more drug-resistant clones, and impact overall survival [16] . We observed delayed postoperative chemotherapy in seven of 56 patients (12.5%) treated with neoadjuvant chemotherapy. The other theoretical disadvantage is that delayed surgery might expose the patient to a large tumor burden for a prolonged period while they undergo potentially marginally effective chemotherapy, which could increase the risk of distant metastasis.
Neoadjuvant Chemotherapy, Risk of Local Recurrence, and Complications
We observed no difference in local recurrence survival between the two groups. Neoadjuvant chemotherapy can help achieve complete resection, and we previously believed that if the tumor responds to the treatment, it would be easier for the surgeon to delineate the tumor during resection. However, we found no advantages in the current study in terms of overall survivorship or the risk of local recurrence in pelvic osteosarcoma. Given that osteoid matrix remains after tumor cell necrosis, osteosarcomas do not shrink, even if chemotherapy is effective. Therefore, an evaluation of chemotherapy response must be performed histologically on the resected tumor specimen. For patients with pelvic lesions, chemotherapy did not seem to achieve as much response in the primary tumor as is seen in extremity lesions, although our study was not designed to show that. Our study showed that 9% of patients were evaluated as objective responders to chemotherapy according to RECIST1.1, and 80% patients experienced stable disease during chemotherapy, which means that no great changes were recorded during chemotherapy. In extremity osteosarcoma, the local recurrence risk has been as low as 5% to 8%, according to several large series [4, 27, 30] . Several studies showed that in osteosarcoma patients with extremity lesions, efficacious neoadjuvant chemotherapy was associated with reduced local recurrence rates and therefore made limb-salvage surgery safer [5, 27] . An inadequate surgical margin was the most important risk factor for local failure. Resection in the pelvic region was much more difficult than in the extremities and the local recurrence rate was as high as 25% to 45% [8, 11, 12, 15, 17, 19, 25, 26, 28] . Poor response to chemotherapy was another risk factor for local recurrence. Several groups found local failure to be one-third as likely in good responders to neoadjuvant chemotherapy compared with poor responders [4, 27, 30] . As for surgical complications, with the numbers available, we could not demonstrate a difference in complications related to surgery timing.
Is 90% Necrosis After Neoadjuvant Chemotherapy a Good Threshold?
In our study, four patients had a necrosis rate of more than 90%. However, if we defined a fair responder as more than 60% necrosis, we observed a better overall prognosis in these fair responders. A 2004 study of pelvic osteosarcoma reached a similar conclusion [8] . As mentioned above, neoadjuvant chemotherapy offers a potential opportunity to evaluate the efficacy of a chemotherapy protocol by assessing the histologic necrosis. Most investigators would define a good response to preoperative chemotherapy as < 10% viable tumor, which was recorded as a necrosis rate of more than 90% [6, 20, 30] . Prior work has shown that at definitive surgery, 65% to 73% of tumors had at least 90% necrosis in the resected specimen of extremity lesions after a multidrug combination [22, 30] . However, in patients with pelvic lesions, the necrosis rate is often much lower. In a study of 25 patients treated by neoadjuvant chemotherapy, none showed more than 90% of tumor necrosis [8] . A report by Fuchs et al. [12] showed that the mean tumor necrosis rate in pelvic osteosarcoma was 37.5% (SD, 35%; range, 0%-100%).
Conclusions
The prognosis of pelvic osteosarcoma remains poor. In our study, where treatment was not randomized but a standard multidrug chemotherapy regimen was administered, we could not demonstrate an advantage in survival, local recurrence, or complications by giving chemotherapy before surgery compared with immediate surgery followed by chemotherapy in patients with nonmetastatic, high-grade pelvic osteosarcoma. In patients who received neoadjuvant chemotherapy, we observed that a histological response of > 60% was associated with an improved prognosis compared with patients with less necrosis. This study supports the contention of other studies in extremity osteosarcoma that adjuvant chemotherapy is effective, but the timing may not matter with respect to survival. A prospective trial is necessary to confirm our observations, but that is unlikely to happen. In the meantime, the treating team should base the use of neoadjuvant chemotherapy on other potential advantages, such as the ability to assess necrosis, having time to plan resection and reconstruction options with the patient, and considerations of anticipated margin status.
